KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Other Non Operating Income: 2018-2025

Historic Other Non Operating Income for Neogenomics (NEO) over the last 8 years, with Sep 2025 value amounting to -$335,000.

  • Neogenomics' Other Non Operating Income fell 205.68% to -$335,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$219,000, marking a year-over-year decrease of 224.43%. This contributed to the annual value of -$379,000 for FY2024, which is 158.85% down from last year.
  • Latest data reveals that Neogenomics reported Other Non Operating Income of -$335,000 as of Q3 2025, which was down 169.50% from $482,000 recorded in Q2 2025.
  • Neogenomics' 5-year Other Non Operating Income high stood at $730,000 for Q2 2023, and its period low was -$4.9 million during Q1 2021.
  • In the last 3 years, Neogenomics' Other Non Operating Income had a median value of -$2,000 in 2024 and averaged $43,364.
  • Per our database at Business Quant, Neogenomics' Other Non Operating Income slumped by 2,276.68% in 2021 and then soared by 24,200.00% in 2025.
  • Quarterly analysis of 5 years shows Neogenomics' Other Non Operating Income stood at -$930,000 in 2021, then surged by 99.89% to -$1,000 in 2022, then soared by 12,500.00% to $124,000 in 2023, then tumbled by 447.58% to -$431,000 in 2024, then plummeted by 205.68% to -$335,000 in 2025.
  • Its Other Non Operating Income stands at -$335,000 for Q3 2025, versus $482,000 for Q2 2025 and $65,000 for Q1 2025.